Erythropoietin and radiotherapy in lung cancer patients

Basit Öğe Kaydı
dc.authoridYalman, Deniz/0000-0002-4010-8353
dc.authoridbolukbasi, yasemin/0000-0002-3170-5826
dc.authorwosidYalman, Deniz/ABG-5077-2020
dc.authorwosidbolukbasi, yasemin/P-2244-2019
dc.contributor.authorYurut-Caloglu, V.
dc.contributor.authorHaydaroglu, A.
dc.contributor.authorOzkok, S.
dc.contributor.authorYalman, D.
dc.contributor.authorBolukbasi, Y.
dc.date.accessioned2024-06-12T11:03:06Z
dc.date.available2024-06-12T11:03:06Z
dc.date.issued2009
dc.departmentTrakya Üniversitesien_US
dc.description.abstractPurpose. To evaluate the effectiveness of recombinant human erythropoietin (rhEPO) in relation to low hemoglobin (Hb) level, overall tumor response rates, and rhEPO adverse events in patients with lung cancer undergoing radiotherapy (RT). Patients and methods: Thirteen consecutive patients were included. All of them had measurable tumor before RT 150 IU/kg of rhEPO-alpha or -beta were administered 3 times per week, 7-10 clays before RT. The target Hb value was 13 g/dl. Tumor response was assessed 6 weeks after completion of RT Results: Response to rhEPO was seen 62% (n=8) of the patients. Weekly mean Hb increment was 0.69 g/dl (range 0.42-1). The mean Hb value during R T was 13.2 g/dl (range 9-14.7) in responding patients, and 10.7 g/dl (range 9.7-11.8) in non-responding patients (p=0.005). Overall response rates to RT were significantly higher in responding than in non-responding patients (p=0.034). Conclusion: rhEPO increased Hb levels in lung cancer patients undergoing RT. However, safety, and more importantly, indications need further clarifications.en_US
dc.identifier.endpage521en_US
dc.identifier.issn1107-0625
dc.identifier.issn2241-6293
dc.identifier.issue3en_US
dc.identifier.pmid19810149en_US
dc.identifier.scopus2-s2.0-70350071769en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage519en_US
dc.identifier.urihttps://hdl.handle.net/20.500.14551/21533
dc.identifier.volume14en_US
dc.identifier.wosWOS:000270421300025en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherImprimatur Publicationsen_US
dc.relation.ispartofJournal Of Buonen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectHemoglobinen_US
dc.subjectLung Canceren_US
dc.subjectRadiotherapyen_US
dc.subjectRhepoen_US
dc.subjectCarcinomaen_US
dc.subjectCervixen_US
dc.titleErythropoietin and radiotherapy in lung cancer patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu